CS
IPXL

Candriam SCA’s Impax Laboratories, Inc. IPXL Stock Holding History

Candriam SCA’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-84,000
Closed -$2.67M – 690
2016
Q1 		$2.67M Buy
84,000
+24,000
+40% +$844K 0.07% 281
2015
Q4 		$2.57M Buy
+60,000
New +$2.4M 0.07% 265

Other funds holding IPXL

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Candriam SCA's IPXL Position: Q2 2016 in Review

Candriam SCA sold out of Impax Laboratories, Inc. (IPXL) in Q2 2016, closing a stake of 84,000 shares — an estimated $2.67M sold.

Candriam SCA first reported a position in IPXL in Q4 2015 and held it in 2 quarters. The position peaked at $2.67M in Q1 2016. 198 funds tracked by Wall St. Rank hold IPXL as of Q2 2016.

  • Candriam SCA reported no remaining Impax Laboratories, Inc. position as of Q2 2016 after selling out during the quarter.
  • Candriam SCA sold 84,000 Impax Laboratories, Inc. shares in Q2 2016, an estimated $2.67M.
  • Candriam SCA first reported a position in Impax Laboratories, Inc. in Q4 2015 and held it in 2 quarters.
  • Candriam SCA's Impax Laboratories, Inc. position peaked at $2.67M in Q1 2016.
  • 198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2016.

Based on Candriam SCA's 13F filing for Q2 2016, filed 26 Jul 2016.